Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis
NCT05321420Phase 2Active, not recruiting
- Sponsor
- PureTech Health
- Start
- Jul 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of deupirfenidone in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by PureTech Health. Primary endpoint: Rate of decline in Forced Vital Capacity at 26 weeks. Started Jul 2022; status: active, not recruiting.
02
Drugs
deupirfenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05321420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05321420.